Short-Term Topical Tetracaine Is Highly Efficacious for the Treatment of Pain Caused by Corneal Abrasions: A Double-Blind, Randomized Clinical Trial.
Administration, Topical
Adolescent
Adult
Aged
Aged, 80 and over
Analgesics
/ administration & dosage
Corneal Injuries
/ complications
Double-Blind Method
Drug Administration Schedule
Eye Pain
/ drug therapy
Female
Follow-Up Studies
Humans
Male
Middle Aged
Pain Measurement
Prospective Studies
Tetracaine
/ administration & dosage
Treatment Outcome
Young Adult
Journal
Annals of emergency medicine
ISSN: 1097-6760
Titre abrégé: Ann Emerg Med
Pays: United States
ID NLM: 8002646
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
19
06
2020
revised:
23
08
2020
accepted:
28
08
2020
pubmed:
31
10
2020
medline:
11
3
2021
entrez:
30
10
2020
Statut:
ppublish
Résumé
The objective of this study is to show that patients with corneal abrasions would experience more pain relief with short-term topical tetracaine than placebo. The study was a prospective, double-blind, randomized trial of tetracaine versus placebo set in the emergency department (ED). A total of 118 adults who presented with uncomplicated corneal abrasions were included and randomized. The intervention was either topical tetracaine or placebo applied every 30 minutes as needed for 24 hours. The primary outcome was the overall numeric rating scale pain score measured at the 24- to 48-hour ED follow-up examination. One hundred eleven patients were included in the final analysis, 56 in the tetracaine group and 55 in the placebo group. At the 24- to 48-hour follow-up, the overall numeric rating scale pain score after use of the study drops was significantly lower in the tetracaine group (1) versus placebo group (8) (Δ7; 95% confidence interval 6 to 8). Patients in the tetracaine group used less hydrocodone than those in the placebo group. The complication rates between the 2 groups were similar. Short-term topical tetracaine is an efficacious analgesic for acute corneal abrasions, is associated with less hydrocodone use compared with placebo, and was found to be safe in this sample.
Identifiants
pubmed: 33121832
pii: S0196-0644(20)30739-3
doi: 10.1016/j.annemergmed.2020.08.036
pii:
doi:
Substances chimiques
Analgesics
0
Tetracaine
0619F35CGV
Banques de données
ClinicalTrials.gov
['NCT04187417']
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
338-344Informations de copyright
Copyright © 2020. Published by Elsevier Inc.